Echocardiographic and biomarker evidence of plasma volume expansion after short‐term steroids administered orally in cats

Block, Chloё L.; Oyama, Mark A.

doi:10.1111/jvim.15678

Cited by 7 publications

(5 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At high ALT concentrations, NT‐proBNP could be partially elevated as a consequence of liver disease, producing a weaker association with DMVD severity 56 . In addition, 15 dogs were receiving treatment with corticosteroids which can affect both variables 57 . This is not the first study to describe changes in ALT associated with the severity of preclinical disease; 6 however, it is possible that this result was in some way confounded.…”

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

“…56 In addition, 15 dogs were receiving treatment with corticosteroids which can affect both variables. 57 This is not the first study to T A B L E 5 The performance of a series of models predicting preclinical disease status was assessed using a locally weighted smoothing line (LOWESS) fitted to predicted probabilities plotted against the actual probability (prevalence) for each value. Support vector machine models were developed using linear, polynomial and radial basis function kernels.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease

Wilshaw

Rosenthal²,

Wess

et al. 2021

Veterinary Internal Medicne

Self Cite

View full text Add to dashboard Cite

Background: Treatment is indicated in dogs with preclinical degenerative mitral valve disease (DMVD) and cardiomegaly (stage B2). This is best diagnosed using echocardiography; however, relying upon this limits access to accurate diagnosis. Objectives: To evaluate whether cardiac biomarker concentrations can be used alongside other clinical data to identify stage B2 dogs. Animals: Client-owned dogs (n = 1887) with preclinical DMVD prospectively sampled in Germany, the United Kingdom, and the United States. Methods: Dogs that met inclusion criteria and were not receiving pimobendan (n = 1245) were used for model development. Explanatory (multivariable logistic Abbreviations: ALKP, alkaline phosphatase; ALT, alanine aminotransferase; AUC, area under the curve; BCS, body condition score; BUN, blood urea nitrogen; CHF, congestive heart failure; CI, confidence interval; CKCS, Cavalier King Charles Spaniel; cTnI, cardiac troponin I; DMVD, degenerative mitral valve disease; EPIC, effect of pimobendan in dogs with preclinical myxomatous mitral valve disease and cardiomegaly; GBM, gradient boosting machine; GGT, gamma-glutamyl transferase; LA:Ao, left atrial to aortic root ratio; LQ, lower quartile, 25th percentile; LVIDD, left ventricular internal diameter at end diastole; LVIDDN, left ventricular internal diameter at end diastole normalized to bodyweight (kg); NT-proBNP, N-terminal propeptide of B-type natriuretic peptide; OR, odds ratio; RAAS, renin angiotensin aldosterone system; SDMA, symmetric dimethylarginine; SVM, support vector machine; UQ, upper quartile, 75th percentile; VHS, vertebral heart score.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease

Wilshaw

Rosenthal²,

Wess

et al. 2021

Veterinary Internal Medicne

Self Cite

View full text Add to dashboard Cite

show abstract

“…38 In cats with a cardio myopathy that have experienced acute heart failure precipitated by a stressful event (eg, cat fight), anesthesia/surgery or fluid administration, the prognosis is also better. 54,122,123 Several variables can be used to help determine poor long-term prognosis regardless of the type of left-sided cardiomyopathy. Severe LA enlargement is a poor prognostic indicator.…”

Section: Prognosismentioning

confidence: 99%

Section: Prognosismentioning

confidence: 99%

The Feline Cardiomyopathies: 1. General concepts

Kittleson

Côté

2021

Journal of Feline Medicine and Surgery

View full text Add to dashboard Cite

Practical relevance: The feline cardiomyopathies are the most prevalent type of heart disease in adult domestic cats. Several forms have been identified (see Parts 2 and 3), with hypertrophic cardiomyopathy (HCM) being the most common. Clinically the cardiomyopathies are often indistinguishable. Cats with subclinical cardiomyopathy may or may not have characteristic physical examination findings (eg, heart murmur, gallop sound), or radiographic cardiomegaly. Cats with severe disease may develop signs of heart failure (eg, dyspnea, tachypnea) or systemic arterial thromboembolism (ATE; eg, pain and paralysis). Sudden death is possible. Treatment usually does not alter the progression from subclinical to clinical disease and often the treatment approach, once clinical signs are apparent, is the same regardless of the type of cardiomyopathy. However, differentiating cardiomyopathy from normal variation may be important prognostically. Patient group: Domestic cats of any age from 3 months upward, of either sex and of any breed, can be affected. Mixed-breed cats are most commonly affected but certain breeds are disproportionately prone to developing HCM. Diagnostics: Subclinical feline cardiomyopathies may be suspected based on physical examination findings, thoracic radiographs and cardiac biomarker results but often the disease is clinically silent. The definitive clinical confirmatory test is echocardiography. Left heart failure (pulmonary edema and/or pleural effusion) is most commonly diagnosed radiographically, but point-of-care ultrasound and amino terminal pro-B-type natriuretic peptide (NT-proBNP) biomarker testing can also be useful, especially when the stress of taking radiographs is best avoided. Key findings: Knowledge of pathophysiological mechanisms helps the practitioner identify the feline cardiomyopathies and understand how these diseases progress and how they manifest clinically (heart failure, ATE). Existing diagnostic tests have strengths and limitations, and being aware of these can help a practitioner deliver optimal recommendations regarding referral. Conclusions: Several types of feline cardiomyopathies exist in both subclinical (mild to severe disease) and clinical (severe disease) phases. Heart failure and ATE are the most common clinical manifestations of severe cardiomyopathy and are therapeutic targets regardless of the type of cardiomyopathy. The long-term prognosis is often guarded or poor once overt clinical manifestations are present. Areas of uncertainty: Some cats with presumed cardiomyopathy do not have echocardiographic features that fit the classic cardiomyopathies (cardiomyopathy – nonspecific phenotype). Although no definitive treatment is usually available, understanding how cardiomyopathies evolve remains worthy of investigation.

show abstract

Oncology

Bryan

2025

The Cat

View full text Add to dashboard Cite

Echocardiographic and biomarker evidence of plasma volume expansion after short‐term steroids administered orally in cats

Cited by 7 publications

References 22 publications

Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease

Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease

The Feline Cardiomyopathies: 1. General concepts

Oncology

Contact Info

Product

Resources

About